Pharma Comes Under Fire for Jump in Rx Prices
Drug manufacturers came under fire at a hearing of the House Energy and Commerce?s health subcommittee for bumping drug prices 10 percent this year. Pharma claims rumors that it?s boosting costs in anticipation of healthcare reform are baseless, but the industry could be facing an uphill battle.
Layoffs and Job Cuts Brewing at Sanofi-Aventis
With the fourth quarter quickly coming to a close, talks of job cuts are once again in the air. The first major layoffs could be coming at Sanofi-Aventis, which is rumored to be slashing up to 1,500 positions.
A Call for Social Media Guidelines
Nearly 70 pharma execs, new media mavens, and even Joe Q. Public packed last week's FDA social media hearings to plead for some form of guidance on how to handle Tweets, blog comments, and off label discussions online.
Pfizer Quick on the Draw with R&D Location Plans
Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network.
J&J Cuts Staff in Major Restructuring Move
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
Jury Sides with Family in Paxil Birth Defect Case
GSK is being ordered to pay $2.5 million in restitution to a Pennsylvania family. The firm was accused of not doing enough to warn consumers that taking the antidepressant Paxil, while pregnant, could lead to birth defects.
Sandoz and Shire settle Adderall XR Dispute
Sandoz Shire Pharmaceuticals announced that it would allow Sandoz to market a generic version of its blockbuster ADHD med Adderall XR if it can clear FDA. But that's a big if.
An Open Conversation
Big Pharma navigates a regulatory minefield to reach social media consumers. It's anything but 'business as usual.'
WHO Pushes H1N1 Flu to Pandemic State
The Word Health Organization just bumped the H1N1 influenza to pandemic alert phase 6 (the highest alert level), making it the first worldwide pandemic in 41 years.
Roche and Genentech Seal the Deal for $46.8 Billion
After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.
Security Spotlight: Q&A with James Christian, Novartis
Pharm Exec talks with James Christian, head of security at Novartis, to learn more about what the company is doing to protect its supply chain and stop counterfeiters
Keeping It Real
Online pharmacies are touting more than just Viagra. Here's what pharma is hoping to do about it
Here are the hottest gadgets and gizmos to make a dent in drug noncompliance
Pharma Not as Fazed by Wall Street Turmoil
Analysts report that Big Pharma isn't being hit that hard by the credit crunch due to the large amount of cash many companies have in their coffers for mergers and acquisitions. However, smaller firms looking to be sold may have a hard time holding out for higher offers.
Vytorin Comes Under Fire Yet Again
A new study shows that while the combo drug decreases the chance of coronary artery disease, it doesn't work as well in slowing down aortic valve disease. So why is all the focus on cancer deaths?
Ad Stars 2008
Pharm Exec shines the spotlight on the creative innovators behind the best pharmaceutical ads of 2007
Rx Club Awards: Human Interest
With ads on topics ranging from addiction to disease states, this year's Rx Club Award winners connect creativity with emotion
Marketing to Professionals: No Sales Force, No Problem
When it comes to direct-mail marketing, tiny envelopes and wordy letters just don't cut it. But for a fraction of the cost of a sales call, you can create an eye-catching mailer that will land on physicians' desks rather than in the circular file.
Creating a breakthrough pharma campaign in today's world of me-too (and me-three and -four) drugs-not to mention marketing mania-forces brand teams to think of new ways to capture consumer and physician attention. In the sleep and cholesterol categories, the competition is so fierce that agencies are using talking beavers and comparing food to family members to stamp brands on consumer brains.
Marketing to Professionals: The Formulary Rebound
Let's face it: no brand manager wants their drug listed on the third or fourth formulary tier. But the reality is that brands often do wind up with low coverage, making them more expensive for consumers.
Pharm Exec Q&A: Inside View
Scientists are worried about what they can and cannot say. Senior scientists feel that if they voice the disagreements that are important to scientific discussion, they might have to leave FDA.
2 Commerce Drive Cranbury, NJ 08512